XOMA Presents New Upbeat Trial Results

|

XOMA Ltd. (Nasdaq: XOMA) presented new upbeat results from Phase 1 studies of its Type 2 diabetes medication lifting shares of the biopharmaceutical up $1.20.

About this Entry

This page contains a single entry by published on June 8, 2009 10:31 AM.

Positive Trial Results For Keryx's Zerenex was the previous entry in this blog.

Analyst Expects Sallie Mae To Continue Servicing Loans is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12